Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reissue Patent
2006-07-04
2006-07-04
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reissue Patent
active
RE039155
ABSTRACT:
Use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of hepatitis B is disclosed.
REFERENCES:
patent: 5039667 (1991-08-01), Tyrrell et al.
patent: 5047407 (1991-09-01), Belleau et al.
patent: 0206497 (1986-12-01), None
patent: 0302760 (1988-06-01), None
patent: 0349242 (1990-01-01), None
patent: 0382526 (1990-08-01), None
patent: 0421739 (1991-04-01), None
patent: 0421777 (1991-04-01), None
patent: 0421819 (1991-04-01), None
patent: 0505181 (1992-09-01), None
patent: 0515144 (1992-11-01), None
patent: 2230266 (1990-10-01), None
patent: WO89/04662 (1989-06-01), None
patent: 2230266 (1990-10-01), None
patent: WO90/12023 (1990-10-01), None
patent: WO92/16215 (1990-10-01), None
patent: WO90/14079 (1990-11-01), None
patent: WO90/14091 (1990-11-01), None
patent: WO91/00282 (1991-02-01), None
patent: WO91/01137 (1991-02-01), None
patent: WO91/01326 (1991-02-01), None
patent: WO91/11186 (1991-08-01), None
patent: WO91/17159 (1991-11-01), None
patent: WO92/08717 (1992-05-01), None
patent: WO92/14743 (1992-09-01), None
patent: WO92/15308 (1992-09-01), None
patent: WO92/18517 (1992-10-01), None
patent: WO92/19246 (1992-11-01), None
Kassianides et al., Abstract: “Effects of 2′,3′-dideoxycytidine on Duck Hepatitis B Virus,” 94 Gastroenterology No. 5, A552 (1988).
Beach et al., “Synthesis of Enantiomerically Pure (2′R, 5′S-(−)-1-[1-(Hydroxymethyl)-oxathiolan-5-yl]cytosine as a Potent Antiviral Agent Against Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV)”, 57 J. Org. Chem., pp. 2217-2219 (1992).
Belleau et al., “Design and Activity of a Novel Class of Nucleoside Analogs Effective Against HIV-1”, Fifth International Conference on AIDS, Montreal, Canada, Abstract T.C.O.1 (1989).
Carlisle et al., “Cellular Pharmacology of the Anti-HIV Agent BCH-189 (2′-Deoxy-3′-Thiacytidine) in Human Peripheral Blood Mononuclear Cells (PBMC)”, American Association for Cancer Research Proceedings, 31 Abstract 2435 (1990).
Chang et al., “Deoxycytidine Deaminase-resistant Stereoisomer is the Active Form of (+/−)-2′,-3′-diedeoxy-3′-thiacytidine in the Inhibition of the Hepatitis B Virus Replication”, 267 J. Biol. Chem., pp. 3938-3942 (1992).
Coats et al., “The Separated Enantiomers of 2′-Deoxy-3′-Thiacytidine (BCH 189) both Inhibit Human Immunodeficiency Virus Replication in Vitro”, 36 Antimicrobial Agents & Chemotherapy, No. 1, pp. 202-205 (1992).
Doong et al., “Inhibition of the Replication of Hepatitis B Virus In-Vitro by 2′3′ Dideoxy-3′-thiacytidine and Related Analogues”, Thirty-first Annual Interscience Conference of Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, Sep. 29-Oct. 2, 1991.
Doong et al., “Inhibition of the Replication of Hepatitis B Virus in vitro by 2′3-dideoxy-3′-thiacytidine and related analogues”, 88 Proc. Natl. Acad. Sci., USA, pp. 8495-8499; 88 Physiology/Pharmacology 8495-8499 (1991).
Greenberg et al., “Metabolism, Toxicity, and Anti-HIV and B Cell Lines”, 616 Annals of the New York Academy of Sciences, 517-518 (1990).
Kassianides et al., “Inhibition of Duck Hepatitis B Virus Replication by 2′3′-dideoxycytidine”, 97 Gastroenterology, No. 5, 1275-1280 (1989).
Lee et al., “In Vitro and In Vivo Comparisons of the Abilities of Purine and Pyrimidine 2′,3′-Dideoxynucleosides To Inhibit Duck Hepadnavirus”, 33 Antimicrobial Agents and Chemotherapy, No. 3, 336-39 (1989).
Soudeyns et al., “Anti-Human Immunodeficiency Virus Type 1 Activity and In Vitro Toxicity of 2′-Deoxy-3′-Thiacytidine (BCH-189), a Novel Heterocyclic Nucleoside Analog”, 35 Antimicrobial Agents and Chemotherapy, No. 7, pp 1386-1390 (1991).
Suzuki et al., “Inhibition of Hepatitis B Virus Replication By Purine 2′,3′-Dideoxynucleosides”, 156 Biochemical and Biophysical Research Communications, 1144-1151 (1988).
Wainberg et al., Abstract, “Anti-HIV-1 Activity, Toxicity and Pharmacokinetics of Totally Novel Nucleoside Analogs”, M.C.P. 63, V International Conference on AIDS, Montreal, Quebec, Canada, Jun. 4-9, 1989.
Wainberg et al., “Characterization of AZT-Resistant Isolates of HIV-1: Susceptibility to Deoxythiacytidine and other Nucleosides”, VI International Conference on AIDS, San Francisco, CA, vol. 3, ABstract SB87, p. 117 (1990).
Sandrstrom et al., “Antiviral Therapy in AIDS: Clinical Pharmacological Properties and Therapeutic Experience to Date”, 34 Drugs, pp 372-390 (1987).
Varmus, “A Growing Role for Reverse Transcription”, 299 Nature, pp. 204-205 (1982).
Higgins, PG, “Interferons”, J. Clin. Pathol., 1984; 37:109-116.
Belleau Pierrette
Nguyen-Ba Nghe
Henley III Raymond J.
millen, White, Zelano, Branigan, P.C.
Shire BioChem Inc.
LandOfFree
Use of 1,3-oxathiolane nucleoside analogues in the treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 1,3-oxathiolane nucleoside analogues in the treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 1,3-oxathiolane nucleoside analogues in the treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3565808